Author Archives: abcuro

Abcuro Founder Reports on the Role of KLRG1+ T cells in Inclusion Body Myositis

Abcuro co-founder Steven A Greenberg, MD and his collaborators have published results of studies on clinical samples in inclusion body myositis (IBM), titled “Highly Differentiated Cytotoxic T Cells in Inclusion Body Myositis”. IBM is an autoimmune disease characterized by T cell infiltration and attack … Read More

Abcuro Founder Reports on the Role of KLRG1+ T cells in Primary Billiary Cholangitis

Abcuro co-founder Steven A Greenberg, MD and his collaborators have published results of studies on clinical samples in primary biliary cholangitis (PBC), titled “Cytotoxic KLRG1 Expressing Lymphocytes Invade Portal Tracts in Primary Biliary Cholangitis”. PBC is an autoimmune disease characterized by T cell … Read More

National Cancer Institute Awards SBIR Grant to Advance Development of KLRG1 Targeted Therapy for Melanoma

Abcuro Inc., announced that it has been awarded a Small Business Innovation Research Grant (SBIR) from the NIH National Cancer Institute. This Phase I grant will support advancement of the company’s anti-KLRG1 blocking antibody (ABC-015) with support for testing in … Read More

ProBioGen and Abcuro sign GlymaxX®-Improved Cell Line Development and GMP Production Agreement

Berlin, Germany, May 23rd, 2019 ProBioGen AG, a premier service and technology provider for complex therapeutic antibodies and glycoproteins, today announced the closing of a services and license agreement with Abcuro, Inc. Pursuing a new generation of immune modulatory bio-therapeutics, … Read More

Abcuro Announces Pre-Clinical Data on New Immuno-Oncology Target KLRG1…

Antibody blockade induces anticancer response in solid tumor models. First in vivo validation of KLRG1 as a cancer immunotherapy target. KLRG1 is a driver of adaptive resistance to immunotherapy in humans. NEWTON, Mass., March 26, 2019 /PRNewswire/ — Abcuro, Inc., a biopharmaceutical … Read More

ABCURO ANNOUNCES $8M SERIES A FINANCING

This financing will advance the preclinical development of their programs in autoimmunity and immuno-oncology. Cambridge, MA – Abcuro, a leading biotechnology company focused on immunology therapeutics, announced the completion of a $8M Series A financing round.  Partners Innovation Fund, Kaitai … Read More